Share Price and Basic Stock Data
Last Updated: January 6, 2026, 7:12 pm
| PEG Ratio | 1.08 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Jagsonpal Pharmaceuticals Ltd operates in the pharmaceuticals sector, with a current market capitalization of ₹1,296 Cr and a share price of ₹194. The company’s revenue from operations reported for the year ending March 2025 stood at ₹269 Cr, reflecting a growth trajectory from ₹237 Cr in March 2023. The trailing twelve months (TTM) revenue reached ₹283 Cr, showcasing consistent upward momentum. Quarterly sales figures indicate fluctuations, with the highest revenue recorded in the March 2025 quarter at ₹76 Cr, while the lowest was ₹43 Cr in the March 2024 quarter. The company’s operating profit margin (OPM) has shown resilience, reported at 22% for the latest fiscal year, which is higher compared to typical sector margins. The sales growth indicates a solid demand for its products, which is critical for sustaining future profitability and market presence.
Profitability and Efficiency Metrics
Jagsonpal Pharmaceuticals reported a net profit of ₹62 Cr with a robust return on equity (ROE) of 18.6% and return on capital employed (ROCE) of 23%. These profitability ratios indicate effective management and operational efficiency, outperforming many peers in the pharmaceutical sector where average ROE tends to hover around 15%. The company has maintained a commendable operating profit (₹51 Cr for FY 2025) with a notable improvement in net profit margin to 20.60%. Additionally, the interest coverage ratio (ICR) stood impressively at 61.86x, indicating that the company generates significantly more income than its interest obligations, showcasing strong financial health. However, the OPM exhibited some volatility, with a decline observed in the December 2023 quarter, where it fell to 7%, signaling potential cost pressures.
Balance Sheet Strength and Financial Ratios
The balance sheet of Jagsonpal Pharmaceuticals reflects a solid foundation, with total reserves recorded at ₹240 Cr against minimal borrowings of ₹9 Cr. The absence of significant debt positions the company favorably, as evidenced by a debt-to-equity ratio of 0.00, which is considerably lower than the industry average. The company’s current ratio is robust at 6.22, indicating strong liquidity, while the quick ratio of 5.64 supports its ability to cover short-term liabilities effectively. Additionally, the book value per share (₹36.08) suggests that the company’s equity is well-supported by its assets, which stood at ₹299 Cr as of September 2025. The overall financial ratios indicate a strong financial position, enhancing investor confidence in the company’s operational stability and growth potential.
Shareholding Pattern and Investor Confidence
Jagsonpal Pharmaceuticals has a diverse shareholding structure, with promoters holding 67.54% of the equity, a slight decline from previous quarters where it was above 68%. Foreign institutional investors (FIIs) have increased their stake to 2.12%, reflecting growing confidence from international investors, while domestic institutional investors (DIIs) remain minimal at 0.08%. The public holding stands at 30.25%, indicating a healthy level of retail investor participation, with the number of shareholders rising significantly to 24,653 as of September 2025. This increase in shareholders suggests a growing interest in the company’s potential. However, the declining promoter holding could raise concerns about long-term commitment, which investors typically monitor closely.
Outlook, Risks, and Final Insight
Looking ahead, Jagsonpal Pharmaceuticals appears well-positioned for growth, supported by its strong financial metrics and increasing revenue trends. However, the company faces risks related to fluctuating operating profit margins, which could impact profitability if cost pressures continue. Additionally, increased competition within the pharmaceutical sector could affect market share and pricing strategies. The reliance on a limited product portfolio may also pose risks if market dynamics change. Nevertheless, the company’s solid balance sheet and strategic positioning in the pharmaceutical industry provide a foundation for sustained growth. Stakeholders should monitor external market conditions and internal operational efficiencies closely to navigate potential challenges effectively.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 131 Cr. | 104 | 214/84.3 | 29.0 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.29/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,602 Cr. | 420 | 479/192 | 95.3 | 24.3 | 0.16 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 35.5 Cr. | 47.9 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 56.0 Cr. | 38.2 | 38.8/17.0 | 133 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,427.05 Cr | 1,147.00 | 54.16 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 61 | 60 | 55 | 60 | 58 | 47 | 43 | 61 | 75 | 74 | 59 | 76 | 74 |
| Expenses | 48 | 52 | 50 | 52 | 49 | 44 | 41 | 51 | 58 | 58 | 50 | 61 | 58 |
| Operating Profit | 13 | 9 | 5 | 9 | 8 | 3 | 3 | 10 | 16 | 16 | 9 | 14 | 16 |
| OPM % | 21% | 14% | 10% | 14% | 14% | 7% | 6% | 17% | 22% | 21% | 15% | 19% | 22% |
| Other Income | 1 | 2 | 3 | 2 | 2 | 3 | 2 | -2 | 2 | 26 | 3 | 3 | 3 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 2 | 2 | 2 |
| Profit before tax | 14 | 10 | 7 | 10 | 10 | 5 | 5 | 7 | 15 | 39 | 9 | 14 | 17 |
| Tax % | 24% | 21% | 24% | 26% | 25% | 25% | 22% | 25% | 25% | 17% | 24% | 25% | 25% |
| Net Profit | 10 | 8 | 6 | 7 | 7 | 4 | 4 | 5 | 11 | 32 | 7 | 11 | 13 |
| EPS in Rs | 1.59 | 1.19 | 0.85 | 1.14 | 1.14 | 0.60 | 0.54 | 0.81 | 1.73 | 4.82 | 0.99 | 1.62 | 1.89 |
Last Updated: January 1, 2026, 5:46 am
Below is a detailed analysis of the quarterly data for Jagsonpal Pharmaceuticals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 74.00 Cr.. The value appears to be declining and may need further review. It has decreased from 76.00 Cr. (Jun 2025) to 74.00 Cr., marking a decrease of 2.00 Cr..
- For Expenses, as of Sep 2025, the value is 58.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 61.00 Cr. (Jun 2025) to 58.00 Cr., marking a decrease of 3.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 16.00 Cr.. The value appears strong and on an upward trend. It has increased from 14.00 Cr. (Jun 2025) to 16.00 Cr., marking an increase of 2.00 Cr..
- For OPM %, as of Sep 2025, the value is 22.00%. The value appears strong and on an upward trend. It has increased from 19.00% (Jun 2025) to 22.00%, marking an increase of 3.00%.
- For Other Income, as of Sep 2025, the value is 3.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 3.00 Cr..
- For Interest, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00 Cr..
- For Depreciation, as of Sep 2025, the value is 2.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 2.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 17.00 Cr.. The value appears strong and on an upward trend. It has increased from 14.00 Cr. (Jun 2025) to 17.00 Cr., marking an increase of 3.00 Cr..
- For Tax %, as of Sep 2025, the value is 25.00%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 25.00%.
- For Net Profit, as of Sep 2025, the value is 13.00 Cr.. The value appears strong and on an upward trend. It has increased from 11.00 Cr. (Jun 2025) to 13.00 Cr., marking an increase of 2.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 1.89. The value appears strong and on an upward trend. It has increased from 1.62 (Jun 2025) to 1.89, marking an increase of 0.27.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:09 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 144 | 138 | 143 | 144 | 127 | 167 | 159 | 188 | 218 | 237 | 209 | 269 | 283 |
| Expenses | 133 | 129 | 132 | 138 | 138 | 157 | 150 | 169 | 192 | 203 | 186 | 218 | 227 |
| Operating Profit | 11 | 9 | 12 | 6 | -11 | 9 | 9 | 19 | 26 | 34 | 23 | 51 | 55 |
| OPM % | 7% | 6% | 8% | 4% | -9% | 6% | 5% | 10% | 12% | 14% | 11% | 19% | 20% |
| Other Income | 0 | 0 | 1 | 13 | 0 | 1 | 3 | 4 | 3 | 2 | 9 | 28 | 34 |
| Interest | 5 | 4 | 5 | 3 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 |
| Depreciation | 3 | 3 | 3 | 2 | 0 | 1 | 1 | 1 | 2 | 1 | 2 | 8 | 9 |
| Profit before tax | 3 | 2 | 4 | 14 | -12 | 9 | 9 | 22 | 27 | 35 | 30 | 70 | 79 |
| Tax % | 16% | 30% | 20% | 18% | -1% | 20% | 16% | 22% | 29% | 23% | 25% | 21% | |
| Net Profit | 2 | 1 | 3 | 12 | -12 | 7 | 8 | 17 | 19 | 27 | 22 | 55 | 62 |
| EPS in Rs | 0.32 | 0.18 | 0.50 | 1.81 | -1.76 | 1.10 | 1.20 | 2.60 | 2.88 | 4.08 | 3.40 | 8.34 | 9.32 |
| Dividend Payout % | 62% | 22% | 8% | 2% | -2% | 9% | 17% | 15% | 56% | 49% | 59% | 30% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -50.00% | 200.00% | 300.00% | -200.00% | 158.33% | 14.29% | 112.50% | 11.76% | 42.11% | -18.52% | 150.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | 250.00% | 100.00% | -500.00% | 358.33% | -144.05% | 98.21% | -100.74% | 30.34% | -60.62% | 168.52% |
Jagsonpal Pharmaceuticals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 11% |
| 3 Years: | 7% |
| TTM: | 35% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 42% |
| 5 Years: | 38% |
| 3 Years: | 29% |
| TTM: | 87% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 36% |
| 5 Years: | 75% |
| 3 Years: | 16% |
| 1 Year: | 45% |
| Return on Equity | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 16% |
| 3 Years: | 17% |
| Last Year: | 19% |
Last Updated: September 5, 2025, 8:00 am
Balance Sheet
Last Updated: December 10, 2025, 2:53 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 |
| Reserves | 85 | 82 | 85 | 97 | 85 | 91 | 98 | 109 | 120 | 146 | 174 | 227 | 240 |
| Borrowings | 36 | 39 | 38 | 8 | 8 | 4 | 5 | 7 | 0 | 6 | 9 | 9 | 9 |
| Other Liabilities | 22 | 19 | 22 | 25 | 23 | 28 | 31 | 35 | 31 | 30 | 21 | 29 | 37 |
| Total Liabilities | 156 | 154 | 159 | 143 | 130 | 136 | 147 | 164 | 164 | 195 | 217 | 278 | 299 |
| Fixed Assets | 56 | 52 | 52 | 22 | 21 | 22 | 22 | 26 | 23 | 24 | 9 | 94 | 90 |
| CWIP | 2 | 0 | 0 | 0 | 3 | 4 | 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 11 | 15 | 51 | 1 | 0 | 0 | 0 |
| Other Assets | 98 | 102 | 108 | 121 | 105 | 110 | 109 | 123 | 91 | 170 | 208 | 184 | 209 |
| Total Assets | 156 | 154 | 159 | 143 | 130 | 136 | 147 | 164 | 164 | 195 | 217 | 278 | 299 |
Below is a detailed analysis of the balance sheet data for Jagsonpal Pharmaceuticals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 13.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 13.00 Cr..
- For Reserves, as of Sep 2025, the value is 240.00 Cr.. The value appears strong and on an upward trend. It has increased from 227.00 Cr. (Mar 2025) to 240.00 Cr., marking an increase of 13.00 Cr..
- For Borrowings, as of Sep 2025, the value is 9.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2025) which recorded 9.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 37.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 29.00 Cr. (Mar 2025) to 37.00 Cr., marking an increase of 8.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 299.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 278.00 Cr. (Mar 2025) to 299.00 Cr., marking an increase of 21.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 90.00 Cr.. The value appears to be declining and may need further review. It has decreased from 94.00 Cr. (Mar 2025) to 90.00 Cr., marking a decrease of 4.00 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 209.00 Cr.. The value appears strong and on an upward trend. It has increased from 184.00 Cr. (Mar 2025) to 209.00 Cr., marking an increase of 25.00 Cr..
- For Total Assets, as of Sep 2025, the value is 299.00 Cr.. The value appears strong and on an upward trend. It has increased from 278.00 Cr. (Mar 2025) to 299.00 Cr., marking an increase of 21.00 Cr..
Notably, the Reserves (240.00 Cr.) exceed the Borrowings (9.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -25.00 | -30.00 | -26.00 | -2.00 | -19.00 | 5.00 | 4.00 | 12.00 | 26.00 | 28.00 | 14.00 | 42.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 115 | 119 | 106 | 100 | 73 | 45 | 49 | 25 | 26 | 32 | 19 | 18 |
| Inventory Days | 173 | 176 | 246 | 295 | 307 | 164 | 191 | 134 | 122 | 82 | 68 | 58 |
| Days Payable | 29 | 42 | 60 | 56 | 54 | 59 | 76 | 82 | 76 | 66 | 35 | 37 |
| Cash Conversion Cycle | 259 | 252 | 292 | 339 | 325 | 150 | 164 | 77 | 72 | 48 | 53 | 39 |
| Working Capital Days | 64 | 68 | 72 | 154 | 149 | 67 | 55 | 32 | 59 | 34 | 52 | 9 |
| ROCE % | 6% | 5% | 7% | 3% | -10% | 9% | 9% | 18% | 20% | 25% | 17% | 23% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Motilal Oswal S&P BSE Healthcare ETF | 83 | 0.04 | 0 | 83 | 2025-04-22 17:25:30 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 5.00 | 5.00 | 5.00 | 5.00 |
| Basic EPS (Rs.) | 8.26 | 8.49 | 10.20 | 7.48 | 6.51 |
| Diluted EPS (Rs.) | 8.22 | 8.46 | 10.20 | 7.48 | 6.51 |
| Cash EPS (Rs.) | 9.56 | 9.13 | 10.66 | 8.06 | 6.71 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 36.08 | 70.88 | 60.65 | 46.96 | 43.55 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 36.08 | 70.88 | 60.65 | 49.95 | 46.54 |
| Dividend / Share (Rs.) | 2.50 | 5.00 | 5.00 | 4.00 | 1.00 |
| Revenue From Operations / Share (Rs.) | 40.47 | 78.94 | 90.36 | 86.30 | 71.74 |
| PBDIT / Share (Rs.) | 8.92 | 12.23 | 15.22 | 11.12 | 8.96 |
| PBIT / Share (Rs.) | 7.70 | 11.61 | 14.76 | 10.54 | 8.76 |
| PBT / Share (Rs.) | 10.52 | 11.30 | 13.29 | 10.43 | 8.35 |
| Net Profit / Share (Rs.) | 8.34 | 8.50 | 10.20 | 7.48 | 6.51 |
| PBDIT Margin (%) | 22.05 | 15.49 | 16.84 | 12.88 | 12.48 |
| PBIT Margin (%) | 19.02 | 14.70 | 16.34 | 12.20 | 12.21 |
| PBT Margin (%) | 25.99 | 14.31 | 14.70 | 12.08 | 11.63 |
| Net Profit Margin (%) | 20.60 | 10.76 | 11.28 | 8.66 | 9.07 |
| Return on Networth / Equity (%) | 23.11 | 11.98 | 16.81 | 15.92 | 14.95 |
| Return on Capital Employeed (%) | 20.26 | 15.50 | 23.10 | 20.55 | 18.54 |
| Return On Assets (%) | 19.89 | 10.34 | 13.70 | 11.62 | 10.38 |
| Total Debt / Equity (X) | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 |
| Asset Turnover Ratio (%) | 1.08 | 1.01 | 1.30 | 1.36 | 1.21 |
| Current Ratio (X) | 6.22 | 10.42 | 5.97 | 3.24 | 2.98 |
| Quick Ratio (X) | 5.64 | 9.63 | 5.22 | 2.37 | 2.25 |
| Inventory Turnover Ratio (X) | 17.80 | 1.24 | 1.24 | 1.36 | 1.31 |
| Dividend Payout Ratio (NP) (%) | 23.89 | 58.31 | 0.00 | 53.50 | 15.35 |
| Dividend Payout Ratio (CP) (%) | 20.83 | 54.29 | 0.00 | 49.63 | 14.91 |
| Earning Retention Ratio (%) | 76.11 | 41.69 | 0.00 | 46.50 | 84.65 |
| Cash Earning Retention Ratio (%) | 79.17 | 45.71 | 0.00 | 50.37 | 85.09 |
| Interest Coverage Ratio (X) | 61.86 | 39.74 | 96.57 | 102.18 | 21.61 |
| Interest Coverage Ratio (Post Tax) (X) | 38.24 | 28.60 | 74.08 | 69.70 | 16.71 |
| Enterprise Value (Cr.) | 1305.18 | 591.93 | 644.85 | 795.42 | 154.96 |
| EV / Net Operating Revenue (X) | 4.86 | 2.84 | 2.72 | 3.52 | 0.82 |
| EV / EBITDA (X) | 22.02 | 18.30 | 16.17 | 27.31 | 6.60 |
| MarketCap / Net Operating Revenue (X) | 5.34 | 3.54 | 3.21 | 3.63 | 1.11 |
| Retention Ratios (%) | 76.10 | 41.68 | 0.00 | 46.49 | 84.64 |
| Price / BV (X) | 5.99 | 3.95 | 4.78 | 6.68 | 1.83 |
| Price / Net Operating Revenue (X) | 5.34 | 3.54 | 3.21 | 3.63 | 1.11 |
| EarningsYield | 0.03 | 0.03 | 0.03 | 0.02 | 0.08 |
After reviewing the key financial ratios for Jagsonpal Pharmaceuticals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. It has decreased from 5.00 (Mar 24) to 2.00, marking a decrease of 3.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 8.26. This value is within the healthy range. It has decreased from 8.49 (Mar 24) to 8.26, marking a decrease of 0.23.
- For Diluted EPS (Rs.), as of Mar 25, the value is 8.22. This value is within the healthy range. It has decreased from 8.46 (Mar 24) to 8.22, marking a decrease of 0.24.
- For Cash EPS (Rs.), as of Mar 25, the value is 9.56. This value is within the healthy range. It has increased from 9.13 (Mar 24) to 9.56, marking an increase of 0.43.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 36.08. It has decreased from 70.88 (Mar 24) to 36.08, marking a decrease of 34.80.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 36.08. It has decreased from 70.88 (Mar 24) to 36.08, marking a decrease of 34.80.
- For Dividend / Share (Rs.), as of Mar 25, the value is 2.50. This value is within the healthy range. It has decreased from 5.00 (Mar 24) to 2.50, marking a decrease of 2.50.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 40.47. It has decreased from 78.94 (Mar 24) to 40.47, marking a decrease of 38.47.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 8.92. This value is within the healthy range. It has decreased from 12.23 (Mar 24) to 8.92, marking a decrease of 3.31.
- For PBIT / Share (Rs.), as of Mar 25, the value is 7.70. This value is within the healthy range. It has decreased from 11.61 (Mar 24) to 7.70, marking a decrease of 3.91.
- For PBT / Share (Rs.), as of Mar 25, the value is 10.52. This value is within the healthy range. It has decreased from 11.30 (Mar 24) to 10.52, marking a decrease of 0.78.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 8.34. This value is within the healthy range. It has decreased from 8.50 (Mar 24) to 8.34, marking a decrease of 0.16.
- For PBDIT Margin (%), as of Mar 25, the value is 22.05. This value is within the healthy range. It has increased from 15.49 (Mar 24) to 22.05, marking an increase of 6.56.
- For PBIT Margin (%), as of Mar 25, the value is 19.02. This value is within the healthy range. It has increased from 14.70 (Mar 24) to 19.02, marking an increase of 4.32.
- For PBT Margin (%), as of Mar 25, the value is 25.99. This value is within the healthy range. It has increased from 14.31 (Mar 24) to 25.99, marking an increase of 11.68.
- For Net Profit Margin (%), as of Mar 25, the value is 20.60. This value exceeds the healthy maximum of 10. It has increased from 10.76 (Mar 24) to 20.60, marking an increase of 9.84.
- For Return on Networth / Equity (%), as of Mar 25, the value is 23.11. This value is within the healthy range. It has increased from 11.98 (Mar 24) to 23.11, marking an increase of 11.13.
- For Return on Capital Employeed (%), as of Mar 25, the value is 20.26. This value is within the healthy range. It has increased from 15.50 (Mar 24) to 20.26, marking an increase of 4.76.
- For Return On Assets (%), as of Mar 25, the value is 19.89. This value is within the healthy range. It has increased from 10.34 (Mar 24) to 19.89, marking an increase of 9.55.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.08. It has increased from 1.01 (Mar 24) to 1.08, marking an increase of 0.07.
- For Current Ratio (X), as of Mar 25, the value is 6.22. This value exceeds the healthy maximum of 3. It has decreased from 10.42 (Mar 24) to 6.22, marking a decrease of 4.20.
- For Quick Ratio (X), as of Mar 25, the value is 5.64. This value exceeds the healthy maximum of 2. It has decreased from 9.63 (Mar 24) to 5.64, marking a decrease of 3.99.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 17.80. This value exceeds the healthy maximum of 8. It has increased from 1.24 (Mar 24) to 17.80, marking an increase of 16.56.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 23.89. This value is within the healthy range. It has decreased from 58.31 (Mar 24) to 23.89, marking a decrease of 34.42.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 20.83. This value is within the healthy range. It has decreased from 54.29 (Mar 24) to 20.83, marking a decrease of 33.46.
- For Earning Retention Ratio (%), as of Mar 25, the value is 76.11. This value exceeds the healthy maximum of 70. It has increased from 41.69 (Mar 24) to 76.11, marking an increase of 34.42.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 79.17. This value exceeds the healthy maximum of 70. It has increased from 45.71 (Mar 24) to 79.17, marking an increase of 33.46.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 61.86. This value is within the healthy range. It has increased from 39.74 (Mar 24) to 61.86, marking an increase of 22.12.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 38.24. This value is within the healthy range. It has increased from 28.60 (Mar 24) to 38.24, marking an increase of 9.64.
- For Enterprise Value (Cr.), as of Mar 25, the value is 1,305.18. It has increased from 591.93 (Mar 24) to 1,305.18, marking an increase of 713.25.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 4.86. This value exceeds the healthy maximum of 3. It has increased from 2.84 (Mar 24) to 4.86, marking an increase of 2.02.
- For EV / EBITDA (X), as of Mar 25, the value is 22.02. This value exceeds the healthy maximum of 15. It has increased from 18.30 (Mar 24) to 22.02, marking an increase of 3.72.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 5.34. This value exceeds the healthy maximum of 3. It has increased from 3.54 (Mar 24) to 5.34, marking an increase of 1.80.
- For Retention Ratios (%), as of Mar 25, the value is 76.10. This value exceeds the healthy maximum of 70. It has increased from 41.68 (Mar 24) to 76.10, marking an increase of 34.42.
- For Price / BV (X), as of Mar 25, the value is 5.99. This value exceeds the healthy maximum of 3. It has increased from 3.95 (Mar 24) to 5.99, marking an increase of 2.04.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 5.34. This value exceeds the healthy maximum of 3. It has increased from 3.54 (Mar 24) to 5.34, marking an increase of 1.80.
- For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.03.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Jagsonpal Pharmaceuticals Ltd:
- Net Profit Margin: 20.6%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 20.26% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 23.11% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 38.24
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 5.64
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 28.5 (Industry average Stock P/E: 54.16)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 20.6%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Innov8 3rd Floor, New Delhi Delhi 110020 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Rajpal Singh Kochhar | Chairman Emeritus |
| Mr. Harsha Raghavan | Chairman & Non-Exe.Director |
| Mr. Manish Gupta | Managing Director |
| Mr. Prithipal Singh Kochhar | Non Executive Director |
| Mr. Debasis Bikash Nandy | Independent Director |
| Ms. Radhika Madhukar Dudhat | Independent Director |
| Ms. Pallavi Dinodia Gupta | Independent Director |
FAQ
What is the intrinsic value of Jagsonpal Pharmaceuticals Ltd?
Jagsonpal Pharmaceuticals Ltd's intrinsic value (as of 06 January 2026) is ₹163.31 which is 12.67% lower the current market price of ₹187.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹1,247 Cr. market cap, FY2025-2026 high/low of ₹302/185, reserves of ₹240 Cr, and liabilities of ₹299 Cr.
What is the Market Cap of Jagsonpal Pharmaceuticals Ltd?
The Market Cap of Jagsonpal Pharmaceuticals Ltd is 1,247 Cr..
What is the current Stock Price of Jagsonpal Pharmaceuticals Ltd as on 06 January 2026?
The current stock price of Jagsonpal Pharmaceuticals Ltd as on 06 January 2026 is ₹187.
What is the High / Low of Jagsonpal Pharmaceuticals Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Jagsonpal Pharmaceuticals Ltd stocks is ₹302/185.
What is the Stock P/E of Jagsonpal Pharmaceuticals Ltd?
The Stock P/E of Jagsonpal Pharmaceuticals Ltd is 28.5.
What is the Book Value of Jagsonpal Pharmaceuticals Ltd?
The Book Value of Jagsonpal Pharmaceuticals Ltd is 38.0.
What is the Dividend Yield of Jagsonpal Pharmaceuticals Ltd?
The Dividend Yield of Jagsonpal Pharmaceuticals Ltd is 1.34 %.
What is the ROCE of Jagsonpal Pharmaceuticals Ltd?
The ROCE of Jagsonpal Pharmaceuticals Ltd is 23.0 %.
What is the ROE of Jagsonpal Pharmaceuticals Ltd?
The ROE of Jagsonpal Pharmaceuticals Ltd is 18.6 %.
What is the Face Value of Jagsonpal Pharmaceuticals Ltd?
The Face Value of Jagsonpal Pharmaceuticals Ltd is 2.00.